Image of a climber swinging from a mouth of a cave


What is glaucoma?

Glaucoma is a disease that damages the eye’s optic nerve, which can be caused by extra fluid that increases pressure in the eye.

Open-angle glaucoma is the most common form of glaucoma. It develops gradually and often goes unnoticed at first. Regular eye exams are important to find early signs of damage to the optic nerve.

Is there a cure for glaucoma?

While there is no cure for glaucoma, studies show that lowering high eye pressure can help reduce the risk of glaucoma-related vision loss. That's why treatment of high eye pressure is very important. Remember, high eye pressure can slowly, but permanently, damage your optic nerve before you notice any change in vision.

What can I do to manage my glaucoma or high eye pressure?

Your doctor can recommend a prescription eye drop to help you manage your glaucoma or high eye pressure. One option is COMBIGAN®.

What is COMBIGAN®?

Twice-daily COMBIGAN® is a prescription treatment proven to lower eye pressure for glaucoma patients who require additional medication.

COMBIGAN® is approved to lower pressure in the eyes of people with primary open-angle glaucoma or ocular hypertension (both conditions involve high pressure in the eye) who require additional or adjunctive IOP-lowering therapy.

IOP=intraocular pressure.

Why did my doctor choose COMBIGAN® therapy?

Prescription eye drops are commonly used to reduce high eye pressure. Adding COMBIGAN® has been proven to help lower eye pressure in patients with glaucoma who require additional eye medication.

How do I use COMBIGAN®?

Apply COMBIGAN® eye drops exactly as your eye doctor prescribed. The recommended dose is 1 drop of COMBIGAN® in the affected eye(s) twice a day, 12 hours apart. If you use more than 1 type of eye drop, just be sure to apply them at least 5 minutes apart.

If you have open-angle glaucoma or ocular hypertension, it is important to continue your COMBIGAN® therapy. Don't skip or stop treatment (unless you have spoken to your doctor). Remembering to use your eye drops is easier if you make it part of your daily routine.

If you wear contact lenses, remove them first, then wait 15 minutes after using COMBIGAN® before you put them back into your eyes.

What are the most common side effects of COMBIGAN®?

In a year-long study, the most common adverse reactions occurring in approximately 5% to 15% of patients (n=385) included:

  • Allergic inflammation of the eye
  • Abnormally large lymph follicles in the mucous membrane lining the inner surface of the eyelid and the exposed surface of the eyeball (also called the conjunctiva)
  • Eye redness
  • Severe itching of the eyes
  • Burning and stinging of the eyes

COMBIGAN® eye drops can be absorbed by your body. Contact your eye care professional right away if you experience any of the following potentially serious side effects:

  • Shortness of breath
  • Visual changes
  • Irregular heartbeat and/or slowing of your heart rate

COMBIGAN® ophthalmic solution may cause fatigue and/or drowsiness. If you drive or perform hazardous work, such as operating machinery, make sure you feel appropriately alert. Ocular hypersensitivity reactions have been reported, with some reported to be associated with an increase in intraocular pressure.

These risks are not the only risks associated with COMBIGAN®. If you experience these or other side effects, you should immediately contact your eye doctor.

How can I save on my COMBIGAN® prescription?

Eligible commercially-insured patients may pay as little as $30* per 90-day prescription fill. To access savings on your COMBIGAN® prescription, enroll online here. You can also enroll for discounts by calling 1-833-DIAL-AYS (1-833-342-5297), or texting SAVINGS to 72428.

*Maximum savings limits apply; patient out-of-pocket expense will vary depending on insurance coverage. Offer valid for patients with commercial prescription insurance coverage and a valid prescription for LUMIGAN® 0.01%, COMBIGAN®, or ALPHAGAN® P 0.1%. Offer not valid for patients enrolled in Medicare, Medicaid, or any other federal, state, or government-funded healthcare program. See At Your Service Savings Program Terms, Conditions, and Eligibility Criteria at

AYS Alerts: Msg and data rates apply. Msg frequency depends on user. Reply HELP for help; reply STOP to cancel. Consent to texts not required to sign up for offer. View our Mobile Terms & Conditions and Privacy Policy.


COMBIGAN® (brimonidine tartrate/timolol maleate ophthalmic solution) 0.2%/0.5% is approved for reducing elevated intraocular pressure (IOP) in patients with glaucoma who require additional or adjunctive IOP-lowering therapy. COMBIGAN® lowers IOP slightly less than taking both brimonidine tartrate three times a day and timolol maleate two times a day.


Contraindications: COMBIGAN® ophthalmic solution should not be used by patients who have or ever had a reactive airway disease including bronchial asthma, chronic bronchitis, emphysema, slow heartbeat, impaired conduction of the heart, heart failure, or impaired pumping of the heart. COMBIGAN® should not be used in patients aged 2 years and younger, or by patients with hypersensitivity to any ingredient in this product.

Warnings and Precautions: Severe respiratory reactions and cardiac reactions, including death due to difficulty breathing and rarely death in association with cardiac failure, have been reported in patients with asthma. Additionally, ophthalmic beta-blockers may impair compensatory tachycardia and increase risk of hypotension. Stimulation of the nervous system may be essential in individuals with diminished heart-pumping ability. In patients without a history of cardiac failure, continued use of beta-blocking agents over a period of time can, in some cases, lead to cardiac failure. Patients with mild or moderate chronic bronchitis, emphysema, or asthma should not take COMBIGAN® ophthalmic solution. COMBIGAN® may worsen symptoms associated with poor circulation. COMBIGAN® patients who have allergies may experience stronger allergy symptoms than they would without COMBIGAN® ophthalmic solution. Patients may experience muscle weakness or fatigue. COMBIGAN® may mask hypoglycemic symptoms in patients with diabetes mellitus. COMBIGAN® may mask certain clinical signs of hyperthyroidism, such as rapid heartbeat. Patients with overactive thyroid who withdraw too abruptly from COMBIGAN® may experience severe hyperthyroid symptoms. Ocular hypersensitivity reactions have been reported with brimonidine tartrate ophthalmic solutions 0.2%, with some reported to be associated with an increase in intraocular pressure. There have been reports of bacterial keratitis associated with the use of multiple-dose containers of topical ophthalmic products. Beta-adrenergic receptor blockade impairs the ability of the heart to respond to general anesthesia in surgical procedures, and some patients have experienced protracted severe hypotension during anesthesia. In patients undergoing elective surgery, gradual withdrawal of beta-adrenergic receptor blocking agents may be recommended.

Adverse reactions: The most common adverse reactions, occurring in approximately 5% to 15% of patients, included allergic inflammation of the eye, abnormally large lymph follicles in the mucous membrane lining the inner surface of the eyelid and the exposed surface of the eyeball (also called the conjunctiva), eye redness, severe itching of the eyes, and burning and stinging of the eyes.

Drug interactions: Blood pressure drugs and drugs that are used to stimulate the heart in cases of heart failure (also called cardiac glycosides) may lower blood pressure. Using COMBIGAN® ophthalmic solution together with beta-blocker drugs, either orally or intravenously, may interrupt beta-receptor activity (beta-blockade) within the body. Oral or intravenous calcium channel blockers that prevent calcium from entering the cells of the heart and blood vessels (calcium antagonists) may cause disturbances in the passage of blood through the heart and/or abnormally low blood pressure. Drugs that significantly decrease fluids of the adrenal gland may produce low blood pressure and/or a noticeably slow heartbeat rate below 60 beats per minute. Using COMBIGAN® with central nervous system depressants may result in an increased effect. Using COMBIGAN® with digitalis, a cardiac stimulant, may have added effects in prolonging the time it takes for blood to pass through the heart. CYP2D6 inhibitors may enhance the effect of beta-blockade within the body. Tricyclic antidepressants may reduce the ability of clonidine to lower blood pressure. Monoamine oxidase inhibitors (a type of antidepressant drug) may result in low blood pressure.

Click here for full COMBIGAN® Prescribing Information.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit or call 1 (800)-FDA-1088.